:INFO
The obesity drug revolution
In 2023 the world discovered that a class of drugs originally designed for diabetes could produce dramatic weight loss. By 2026 the category has expanded from first-generation weekly injections to oral pills, second-generation dual-agonists, and a third-generation triple-agonist called retatrutide that in trials produced average weight loss of around 24 percent of body weight. This slate ranks the main options by mechanism, efficacy, and current status.


:CHECKLIST
The main drugs in order of generation
[ ] 1. Semaglutide (Ozempic / Wegovy) - GLP-1 agonist, first gen, weekly injection
[ ] 2. Tirzepatide (Mounjaro / Zepbound) - GLP-1 plus GIP dual agonist, second gen
[ ] 3. Liraglutide (Saxenda) - older GLP-1, daily injection, less weight loss
[ ] 4. Orforglipron - oral GLP-1, once daily pill, phase 3 data strong
[ ] 5. Semaglutide oral (Rybelsus) - pill form, lower efficacy than injection
[ ] 6. Retatrutide - triple agonist (GLP-1, GIP, glucagon), phase 3 ongoing

:STATS

:QUOTE [quotetype:plain, subtitle:Dr. Ania Jastreboff]
We are in the middle of a complete transformation in how we treat obesity. These are not diet drugs. They are true medications for a chronic disease.


:LINK
https://www.nejm.org/doi/full/10.1056/NEJMoa2215722
NEJM: Phase 3 tirzepatide results